Why HIV Screening Is Recommended Once for Almost Every Adult

HIV can be present for years without obvious symptoms. During that time, untreated infection can damage the immune system and can be transmitted to others. Reliable testing can identify infection earlier, and modern antiretroviral therapy can preserve health and prevent sexual transmission when treatment produces a sustained undetectable viral load.

Those facts support routine screening rather than waiting for symptoms or asking a clinician to decide who "looks at risk." CDC recommends that all patients ages 13 to 64 be tested at least once as part of routine care. The U.S. Preventive Services Task Force recommends screening adolescents and adults ages 15 to 65, plus younger or older people with risk factors, and gives screening an A grade. Both recommend testing during pregnancy.

The slightly different age ranges do not create a meaningful contradiction. They come from different recommendation frameworks. The shared message is that HIV testing belongs in ordinary preventive care for nearly everyone, with repeat testing when risk continues or a new event creates a window-period question.

Why broad screening replaced risk-only testing#

Risk-based testing remains important, but it cannot carry the whole program. You may not recognize an event as relevant, may never be asked, or may reasonably hesitate to disclose something private. Clinicians can also rely on stereotypes and miss infection in people outside a presumed group.

Routine screening changes the default. The test is offered to you because it is recommended for your age group, not because a clinician has inferred something about your identity or behavior. CDC recommends an opt-out approach in routine care: you are told that testing will be performed unless you decline, subject to current local requirements.

Normalizing the offer can reduce stigma and improve earlier diagnosis. It must still preserve knowledge, privacy, and choice. Routine does not mean secret, compulsory, or exempt from a clear explanation.

What USPSTF and CDC each recommend#

USPSTF recommends HIV screening for adolescents and adults ages 15 through 65. It also recommends screening younger adolescents and adults older than 65 when risk factors are present. All pregnant people should be screened, including those who present in labor with unknown HIV status.

CDC's routine health-care age range is 13 through 64, and it recommends at least annual screening for people with ongoing risk and supports more frequent testing for some people based on their risk and prevention plan.

An age boundary is not a biological switch. A 66-year-old with a new partner or a 12-year-old with relevant risk needs evaluation, while a 30-year-old with no continuing risk and a documented negative screen may have completed the routine one-time recommendation until circumstances change.

Screening and diagnostic testing are not identical#

Screening is testing someone without symptoms or a known immediate event because disease can be present. Diagnostic testing addresses a specific concern, such as a recent possible contact, symptoms compatible with acute HIV, a reactive prior test, or a condition associated with higher HIV likelihood.

This distinction changes test choice and timing. A routine antigen-antibody screen may be appropriate at a preventive visit. After a very recent event, the same negative screen may be too early, and a nucleic acid test or later repeat testing may be needed. The distinction also protects against false reassurance. "My annual screen was negative" does not answer whether infection arose after your sample was collected.

The first laboratory test looks for antigen and antibodies#

The recommended U.S. laboratory algorithm generally begins with a combination immunoassay that detects antibodies to HIV-1 and HIV-2 plus HIV-1 p24 antigen; the antigen can appear before antibodies, helping identify some early infections sooner than an antibody-only test.

A nonreactive result usually ends the routine laboratory algorithm when there is no concern for very early infection. A reactive result is preliminary and moves to supplemental testing. It should not be communicated as a final diagnosis before the algorithm is complete.

Rapid tests and self-tests serve important access and privacy needs. Many self-tests detect antibody only and may become reactive later than a laboratory antigen-antibody assay. The kind of test matters when timing is recent.

The supplemental sequence determines what the screen means#

After a reactive laboratory antigen-antibody test, CDC recommends an HIV-1/HIV-2 antibody differentiation immunoassay, and this confirms antibody and distinguishes HIV-1 from HIV-2 when possible, which matters because monitoring and treatment considerations differ.

If the first test is reactive but the differentiation assay is nonreactive or indeterminate, a diagnostic HIV-1 nucleic acid test is used. Detected HIV-1 RNA in that pattern supports acute HIV-1 infection. RNA not detected usually means the initial screen was falsely reactive for HIV-1, with additional assessment if HIV-2 or another issue remains plausible. The sequence prevents two opposite errors: dismissing early infection because antibodies are not yet confirmed and labeling a false-reactive screen as HIV. Reflex laboratory workflows help complete it on the original sample.

Every HIV test has a window period#

After infection begins, there is a period when a test cannot yet detect its target. Nucleic acid tests generally detect infection earliest, followed by laboratory antigen-antibody tests, then antibody-only tests. Exact timing varies by assay, specimen, person, and use of antiretroviral medicines.

CDC gives typical windows in the absence of antiretroviral medicines: about 10 to 33 days for a nucleic acid test, 18 to 45 days for a laboratory antigen-antibody test using blood from a vein, and 23 to 90 days for an antibody test. These ranges are not promises that every infection will be detected at the first day.

A clinician interprets the result from the date of the most recent possible contact, the test type, symptoms, and any use of pre-contact or post-contact prevention, so a repeat plan should be stated rather than leaving you to guess when a negative result becomes conclusive.

Acute HIV can resemble an ordinary viral illness#

Some people develop fever, rash, sore throat, swollen lymph nodes, headache, muscle aches, diarrhea, or other influenza-like symptoms during acute infection. Others have no recognized symptoms. These findings are nonspecific and occur with many infections.

When a recent possible contact and compatible illness raise concern, CDC recommends HIV RNA testing even if an initial antigen-antibody or antibody result is negative or indeterminate. A routine test report does not imply that RNA was automatically checked after a nonreactive screen. Severe illness needs evaluation on its own merits. Symptom lists should not be used to self-diagnose HIV or decide that testing is unnecessary.

Who needs repeat screening#

People with ongoing risk should be tested at least annually under CDC guidance. Some may benefit from testing every three to six months, particularly as part of pre-contact prevention care or when current sexual or injection practices create continuing risk.

Repeat testing can also follow a newly diagnosed sexually transmitted infection, a new partner, shared injection equipment, a partner with HIV who is not known to have sustained viral suppression, sexual assault, or another clinically relevant event. The plan should be individualized without moral judgment.

You can ask for a test without first proving that you are at risk. Easy access is part of prevention. A negative result is also an opportunity to discuss condoms, sterile equipment, pre-contact prevention, and vaccinations or screening for other infections when relevant.

Pregnancy changes the urgency and schedule#

USPSTF recommends screening all pregnant people, including those with no previously known risk. Early diagnosis allows treatment that supports the pregnant person's health and markedly reduces perinatal transmission.

People with higher likelihood of acquiring HIV during pregnancy should be retested in the third trimester under CDC-related guidance. Rapid testing at labor is used when status is unknown so that time-sensitive management can begin. A negative result from a prior pregnancy does not replace testing in the current pregnancy. A reactive result requires prompt completion of the diagnostic algorithm and specialist-supported treatment, not delay while symptoms are awaited.

Post-contact prevention is time-sensitive#

A possible sexual, injection-related, or other substantial contact with HIV within the prior 72 hours can require urgent assessment for post-contact prophylaxis. CDC recommends starting it as soon as possible when indicated and no later than 72 hours after the event. Testing is part of the visit, but waiting for the end of a window period would miss the prevention opportunity.

The decision considers the contact, source information if available, timing, your current medicines, your kidney and liver health, and whether ongoing prevention will be needed afterward. Emergency departments, urgent care, sexual-health services, and other clinical settings may provide access.

This article cannot determine whether one event qualifies. When timing is within 72 hours, seek prompt clinical advice rather than relying on an online risk calculator.

A positive diagnosis should link directly to treatment#

Current guidance recommends antiretroviral therapy for all people with HIV, started as soon as possible after diagnosis with appropriate evaluation. Treatment suppresses viral replication, protects immune function, and prevents illness.

When a person maintains an undetectable viral load through treatment, they do not sexually transmit HIV, summarized as Undetectable equals Untransmittable. This is a prevention outcome supported by large bodies of evidence, not merely a motivational phrase.

Linkage includes confirmatory results, baseline laboratory assessment, resistance and coinfection considerations, a medication plan, support for adherence and access, and respectful partner services. The value of screening is lost when a result becomes an unsupported notification.

Testing should reduce stigma, not reproduce it#

HIV status is health information. Clinics need private conversations, neutral language, secure results, and clear consent practices. Current state testing rules can differ, so health systems should verify local requirements rather than rely on a generic national script.

No result justifies discrimination. HIV is not spread through hugging, shared food, toilets, ordinary workplace contact, or casual household interaction. Accurate transmission information protects both the person diagnosed and the community. Routine screening works best when it is paired with prevention options and ordinary follow-up, not when it is presented as a special test for a presumed group.